UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000018178 |
|---|---|
| Receipt number | R000021016 |
| Scientific Title | Prospective observational Study to explore the efficacy of Eribulin as 1st-line or 2nd-line chemotherapy in patients with HER2-negative hormone-resistant inoperable or recurrent metastatic breast cancer |
| Date of disclosure of the study information | 2015/07/06 |
| Last modified on | 2022/05/03 15:40:15 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2015/07/03 12:46:37 | ||
| 2 | Update | 2017/07/04 09:03:44 | Name of primary person or sponsor Organization |
|
| 3 | Update | 2019/12/22 15:49:50 | Recruitment status Date of IRB Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
| 4 | Update | 2019/12/22 15:55:36 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Co-sponsor Co-sponsor Organization Organization Address Address Tel Org. issuing International ID_2 Org. issuing International ID_2 |
|
| 5 | Update | 2022/05/03 15:39:38 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
| 6 | Update | 2022/05/03 15:40:01 | Recruitment status |
|
| 7 | Update | 2022/05/03 15:40:15 | Publication of results |
